Ascelia Pharma AB
Pharmaceutical ManufacturingSweden11-50 Employees
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). About Orviglance (Mangoral) Orviglance* (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Orviglance, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study. About Oncoral Oncoral is a novel oral irinotecan tablet in development. Irinotecan is a chemotherapy with established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily tablet with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Oncoral is initially developed for the treatment of gastric cancer, a cancer form with unmet needs and the opportunity for Orphan Drug status in the US and Europe. Following successful Phase 1 results, Phase 2 clinical development for Oncoral is in preparation. *Trademark is registered in Europe and several other markets and submitted for registration in the US.
1-888-653-2347 
support@leadiq.com 
